EpiPen provides 40% of MYL’s operating income, according to Bloomberg: http://www.bloomberg.com/news/articles/2015-09-23/how-marketing-turned-the-epipen-into-a-billion-dollar-business The 40% figure must refer to MYL as it existed before its “spinversion” with ABT.